Raloxifene, a selective estrogen receptor modulator, is renoprotective: A post-hoc analysis

Kidney International

Volumn 79, Issue 2, 2011, Pages 241-249

  Melamed, Michal L ^a   Blackwell, Terri ^b   Neugarten, Joel ^a   Arnsten, Julia H ^a   Ensrud, Kristine E ^c   Ishani, Areef ^c   Cummings, Steven R ^b   Silbiger, Sharon R ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

randomized controlled trials; renal function decline; risk factors

Indexed keywords

CREATININE; PLACEBO; RALOXIFENE;

ADULT; AGED; ALBUMINURIA; ANURIA; ARTICLE; CREATININE BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; FEMALE; FOLLOW UP; GLOMERULITIS; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; KIDNEY TUBULE NECROSIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OSTEOPOROSIS; POST HOC ANALYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; SIDE EFFECT; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL; UREMIA;

EID: 78650871843     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.378     Document Type: Article

References (42)

1. Meguid El Nahas A, Bello AK. Chronic kidney disease: the global challenge. Lancet 2005; 365: 331-340.
2. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047. (Pubitemid 350074801)
3. Collins AJ, Kasiske B, Herzog C et al. Excerpts from the United States Renal Data System 2004 annual data report: atlas of end-stage renal disease in the United States. Am J Kidney Dis 2005; 45: A5-A7.
4. Neugarten J, Acharya A, Silbiger SR. Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. J Am Soc Nephrol 2000;11: 319-329.
5. Haroun MK, Jaar BG, Hoffman SC et al. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol 2003;14: 2934-2941.
6. Eriksen BO, Ingebretsen OC. The progression of chronic kidney disease: a10-year population-based study of the effects of gender and age. Kidney Int 2006; 69: 375-382.
7. Ahmed SB, Culleton BF, Tonelli M et al. Oral estrogen therapy in postmenopausal women is associated with loss of kidney function. Kidney Int 2008; 74: 370-376.
8. Silbiger SR, Neugarten J. The role of gender in the progression of renal disease. Adv Ren Replace Ther 2003;10: 3-14.
9. Baylis C. Age-dependent glomerular damage in the rat. Dissociation between glomerular injury and both glomerular hypertension and hypertrophy. Male gender as a primary risk factor. J Clin Invest1994; 94:1823-1829.
10. Sakemi T, Ohtsuka N, Shouno Y et al. Effect of ovariectomy on glomerular injury in hypercholesterolemic female Imai rats. Nephron1996; 72: 72-78.
11. Iams SG, Wexler BC. Inhibition of the development of spontaneous hypertension in SH rats by gonadectomy or estradiol. J Lab Clin Med1979; 94: 608-616.
12. Khovidhunkit W, Shoback DM. Clinical effects of raloxifene hydrochloride in women. Ann Intern Med1999;130: 431-439.
13. Silbiger S, Lei J, Ziyadeh FN et al. Estradiol reverses TGF-beta1-stimulated type IV collagen gene transcription in murine mesangial cells. Am J Physiol1998; 274: F1113-F1118.
14. Silbiger S, Lei J, Neugarten J. Estradiol suppresses type I collagen synthesis in mesangial cells via activation of activator protein-1. Kidney Int1999; 55:1268-1276. (Pubitemid 29157124)
15. Neugarten J, Acharya A, Lei J et al. Selective estrogen receptor modulators suppress mesangial cell collagen synthesis. Am J Physiol Renal Physiol 2000; 279: F309-F318.
16. Chin M, Isono M, Isshiki K et al. Estrogen and raloxifene, a selective estrogen receptor modulator, ameliorate renal damage in db/db mice. Am J Pathol 2005;166:1629-1636.
17. Dixon A, Wells CC, Singh S et al. Renoprotective effects of a selective estrogen receptor modulator, raloxifene, in an animal model of diabetic nephropathy. Am J Nephrol 2007; 27:120-128.
18. Ishani A, Blackwell T, Jamal SA et al. The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol 2008;19:1430-1438.
19. Delmas PD, Ensrud KE, Adachi JD et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002; 87: 3609-3617.
20. Hadjadj S, Gourdy P, Zaoui P et al. Effect of raloxifene - a selective oestrogen receptor modulator - on kidney function in post-menopausal women with Type 2 diabetes: results from a randomized, placebocontrolled pilot trial. Diabet Med 2007; 24: 906-910.
21. Schopick EL, Fisher ND, Lin J et al. Post-menopausal hormone use and albuminuria. Nephrol Dial Transplant 2009; 24: 3739-3744.
22. Szekacs B, Vajo Z, Varbiro S et al. Postmenopausal hormone replacement improves proteinuria and impaired creatinine clearance in type 2 diabetes mellitus and hypertension. BJOG 2000;107:1017-1021.
23. Manning PJ, Sutherland WH, Allum AR et al. HRT does not improve urinary albumin excretion in postmenopausal diabetic women. Diabetes Res Clin Pract 2003; 60: 33-39.
24. Ahmed SB, Hovind P, Parving HH et al. Oral contraceptives, angiotensindependent renal vasoconstriction, and risk of diabetic nephropathy. Diabetes Care 2005; 28:1988-1994.
25. Black LJ, Sato M, Rowley ER et al. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest1994; 93: 63-69.
26. Zheng F, Plati AR, Potier M et al. Resistance to glomerulosclerosis in B6 mice disappears after menopause. Am J Pathol 2003;162:1339-1348.
27. Tofovic SP, Salah EM, Dubey RK et al. Estradiol metabolites attenuate renal and cardiovascular injury induced by chronic nitric oxide synthase inhibition. J Cardiovasc Pharmacol 2005; 46: 25-35.
28. Gross ML, Adamczak M, Rabe T et al. Beneficial Effects of Estrogens on Indices of Renal Damage in Uninephrectomized SHRsp Rats. J Am Soc Nephrol 2004;15: 348-358.
29. Tofovic SP, Dubey R, Salah EM et al. 2-Hydroxyestradiol attenuates renal disease in chronic puromycin aminonucleoside nephropathy. J Am Soc Nephrol 2002;13: 2737-2747.
30. Elliot SJ, Karl M, Berho M et al. Estrogen deficiency accelerates progression of glomerulosclerosis in susceptible mice. Am J Pathol 2003;162:1441-1448.
31. Blush J, Lei J, Ju W et al. Estradiol reverses renal injury in Alb/TGF-beta1 transgenic mice. Kidney Int 2004; 66: 2148-2154.
32. Kwan G, Neugarten J, Sherman M et al. Effects of sex hormones on mesangial cell proliferation and collagen synthesis. Kidney Int1996; 50:1173-1179.
33. Guccione M, Silbiger S, Lei J et al. Estradiol upregulates mesangial cell MMP-2 activity via the transcription factor AP-2. Am J Physiol Renal Physiol 2002; 282: F164-F169.
34. Potier M, Elliot SJ, Tack I et al. Expression and regulation of estrogen receptors in mesangial cells: influence on matrix metalloproteinase-9. J Am Soc Nephrol 2001;12: 241-251.
35. Zdunek M, Silbiger S, Lei J et al. Protein kinase CK2 mediates TGF-beta1- stimulated type IV collagen gene transcription and its reversal by estradiol. Kidney Int 2001; 60: 2097-2108.
36. Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Jama1999; 282: 637-645.
37. Barrett-Connor E, Mosca L, Collins P et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355:125-137. (Pubitemid 44050394)
38. Udell JA, Fischer MA, Brookhart MA et al. Effect of the Women's Health Initiative on osteoporosis therapy and expenditure in Medicaid. J Bone Miner Res 2006; 21: 765-771.
39. Cummings SR, Eckert S, Krueger KA et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. Jama1999; 281: 2189-2197.
40. Levey AS, Coresh J, Balk E et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139:137-147.
41. National Technical Information Service. Coding Symbols for a Thesaurus of Adverse Reaction Terms (COSTART), 4th edn,1992. National Technical Information Service: Springfield, VA.
42. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics1982; 38: 963-974.